Exhibitors Search
CEFO Co., Ltd.
Booth no.
B61
|
Exhibition
|
|NextRegenX |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|45-13 Ujeongguk-ro, Jongno-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-1032668573-- |
|
Exhibits
|
| Stem Cell-based Bone Regeneration Therapy and NK Cell Immunotherapy |
|
Company Type
|
| Biotech Venture / Startup |
Exhibitor Information
CEFObio Co., Ltd. is an advanced biotechnology company developing allogeneic cell therapies for musculoskeletal diseases. Using umbilical cord-derived mesenchymal stem cells and its 3D hydrogel-based QuickDiff™ platform, CEFObio develops tissue-specific therapies for bone, cartilage, ligaments, and tendons.
Its key pipeline, CF-M801, is an allogeneic osteoblast cell therapy currently in Phase 2 clinical trials in Korea for osteonecrosis of the femoral head. CEFObio is also preparing for a Phase 2a trial for fragility hip fractures and conducting preclinical studies for spinal diseases.
The company operates GMP manufacturing and cell processing facilities, supporting clinical manufacturing and CDMO collaboration. It also develops and supplies cell therapy materials, including cell culture media, enzymes, and cryopreservation systems. CEFObio maintains a systematic manufacturing and quality management system based on ISO 9001, ISO 13485, and ISO 22716 certifications.
Its key pipeline, CF-M801, is an allogeneic osteoblast cell therapy currently in Phase 2 clinical trials in Korea for osteonecrosis of the femoral head. CEFObio is also preparing for a Phase 2a trial for fragility hip fractures and conducting preclinical studies for spinal diseases.
The company operates GMP manufacturing and cell processing facilities, supporting clinical manufacturing and CDMO collaboration. It also develops and supplies cell therapy materials, including cell culture media, enzymes, and cryopreservation systems. CEFObio maintains a systematic manufacturing and quality management system based on ISO 9001, ISO 13485, and ISO 22716 certifications.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Allogeneic osteoblast cell therapy CF-M801QuickDiff™-Based Off-the-Shelf Allogeneic Osteogenic Progenitor Cell Therapy ◈ Derived from umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs), with osteogenic progenitor cells produced within 3?5 days using a 3D hydrogel-based differentiation technology. ◈ Standardized as a ready-to-use formulation that can be thawed and used immediately after cryopreservation, making it suitable for standardized and large-scale manufacturing. ◈ Phase 1 clinical trial for osteonecrosis of the femoral head (ONFH) completed; Phase 2 clinical trial ongoing in Korea. Designated as an orphan drug in Korea (2022) and the EU (2025).
KYUNGYON EXHIBITION CORP.
